Gufic BioSciences Ltd
Gufic BioSciences Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #44 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Company targets 15% to 20% year-over-year revenue growth as a bare minimum, with efforts ongoing to exceed 20% growth. The company targets a year-on-year growth of 15% to 20% as a bare minimum, with efforts underway to exceed 20%.
From Gufic BioSciences Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Company targets 15% to 20% year-over-year revenue growth as a bare minimum, with efforts ongoing to exceed 20% growth.
- Indore facility capacity utilization is expected to increase from around 30-35% to close to 80% in the next 2-3 years, improving operating leverage.
- Revenue extraction from Indore alone is projected between INR 800 crores to INR 1,200 crores without additional capex.
- Overall revenue potential combining existing product mix and legacy capacity is estimated between INR 1,600 crores to INR 2,000 crores.
- Product mix improvements aiming to increase average revenue per vial from INR 80-100 to INR 300-500 to drive further growth.
- Expansion into complex injectables, depot, and liposomal products expected to contribute 20-30% of production by FY28.
2 more points from Gufic BioSciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Gufic BioSciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex around INR 300 crore mainly for Indore and Navsari facilities.
- No major new infrastructure or equipment capex planned; focus is on adding new product lines (depot and liposomal injections) within existing capex.
- Capacity expansion by introducing depot and liposomal products in lyophilization lines.
- Indore plant fully operational; ongoing validation batches for depot and liposomal products.
2 more points from Gufic BioSciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gufic BioSciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Gufic BioSciences Ltd's call on order book
Create a free account to keep reading this call
Gufic BioSciences Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹231 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gufic BioScience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gufic BioSciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gufic BioSciences Ltd Q1 FY27 results?
Company targets 15% to 20% year-over-year revenue growth as a bare minimum, with efforts ongoing to exceed 20% growth. The company targets a year-on-year growth of 15% to 20% as a bare minimum, with efforts underway to exceed 20%.
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 58.9 with a market cap of ₹4,327 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
Current capex around INR 300 crore mainly for Indore and Navsari facilities.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.